Patenting antibody combination therapies.

There is emerging, intense interest in antibody combination therapies. However, antibody combination therapies pose unique intellectual property challenges. In some instances, it may be difficult to obtain patents with claims that provide innovators with adequate protection for such inventions.

Zebrafish V2 cells develop into excitatory CiD and Notch signalling dependent inhibitory VeLD interneurons.

The vertebrate spinal cord contains distinct classes of cells that form at precise dorsal-ventral locations and express specific combinations of transcription factors. In amniotes, V2 cells develop in the ventral spinal cord, just dorsal to motoneurons. All V2 cells develop from the same progenitor domain and hence are initially molecularly identical.